Home / World / Cystic Fibrosis Drug Costs Drop: Hope & Affordability for Families

Cystic Fibrosis Drug Costs Drop: Hope & Affordability for Families

Cystic Fibrosis Drug Costs Drop: Hope & Affordability for Families

Table of Contents

Okay, here’s ⁢a breakdown of the key facts from the​ provided text, focusing on the central themes and arguments:

Main Topic: The global effort to make affordable generic versions of Cystic Fibrosis (CF) drugs, specifically ETI (Elta-tezacaftor/Ivacaftor, a CFTR modulator like Trikafta), available to⁢ patients worldwide.

Key Players ​& Organizations:

* Vertex Pharmaceuticals: The original ⁣manufacturer of CF drugs like orkambi,Symkevi,and Trikafta. They argue their high prices are justified by the substantial R&D costs.
* NHS England: Had protracted, tough negotiations with Vertex over Orkambi in 2019.
*‌ CF Buyers’ Club (1.0 & 2.0): Initially a UK-based group of families who pooled resources to buy a cheaper, generic version of Orkambi from ⁤Argentina. It‌ has now evolved into a ‌global movement.
* ‌ Gayle⁤ Pledger: A UK parent and key campaigner‌ with Just Treatment, instrumental in the effort to secure a generic ETI.
* Beximco: A Bangladeshi pharmaceutical company that will manufacture a ‌generic version of ETI ⁤(Triko) at a substantially lower cost.
* Just Treatment: A campaign ‌group working to improve‌ access⁢ to medicines.
* Third World Network: ‍ A campaign⁣ group ‌that assisted Just Treatment in approaching Beximco.

Key Arguments & ⁢Points:

* High Drug Costs & Inaccessibility: Vertex’s CF drugs are very expensive (around ⁢$60,000/year) and unaffordable‍ for many, especially in low- and‌ middle-income countries.This ⁣has led to suffering ⁣and ‌death among CF patients⁢ who could benefit from the treatment.
* ‍ The Role of Generics: generic versions of ETI, like Triko, offer a dramatically⁢ cheaper alternative (around ‌$6,375 – $12,750/year).
* The Power of patient Advocacy: The CF Buyers’ Club, ⁣driven by parents and families, has been a crucial force in pushing for access to affordable medication. Their collective action has‍ been described‍ as a powerful force.
* Intellectual⁤ Property & Manufacturing: Bangladesh’s⁤ status as a​ “least⁣ developed country” allows it to bypass some international intellectual property laws, enabling Beximco to produce‌ a⁣ generic version. Importation for personal use is permitted in many‍ countries.
* Undiagnosed Cases: A significant number of people (almost 80,00

Also Read:  Epstein Files: DOJ Release - What We Know

Leave a Reply